rs147314661
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PM1PM2
The NM_001122955.4(BSCL2):c.299G>T(p.Cys100Phe) variant causes a missense change. The variant allele was found at a frequency of 0.0000366 in 1,614,106 control chromosomes in the GnomAD database, including 1 homozygotes. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. C100Y) has been classified as Uncertain significance.
Frequency
Consequence
NM_001122955.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 4 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
BSCL2 | NM_001122955.4 | c.299G>T | p.Cys100Phe | missense_variant | 2/11 | ENST00000360796.10 | |
HNRNPUL2-BSCL2 | NR_037946.1 | n.2819G>T | non_coding_transcript_exon_variant | 15/24 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
BSCL2 | ENST00000360796.10 | c.299G>T | p.Cys100Phe | missense_variant | 2/11 | 1 | NM_001122955.4 | A2 |
Frequencies
GnomAD3 genomes AF: 0.000210 AC: 32AN: 152228Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000119 AC: 3AN: 251270Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135850
GnomAD4 exome AF: 0.0000185 AC: 27AN: 1461878Hom.: 1 Cov.: 31 AF XY: 0.0000220 AC XY: 16AN XY: 727238
GnomAD4 genome AF: 0.000210 AC: 32AN: 152228Hom.: 0 Cov.: 32 AF XY: 0.000229 AC XY: 17AN XY: 74374
ClinVar
Submissions by phenotype
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 27, 2021 | The c.107G>T (p.C36F) alteration is located in exon 2 (coding exon 1) of the BSCL2 gene. This alteration results from a G to T substitution at nucleotide position 107, causing the cysteine (C) at amino acid position 36 to be replaced by a phenylalanine (F). The heterozygous missense change is ultra rare in population databases:_x000D_ _x000D_ Based on data from the Genome Aggregation Database (gnomAD), the BSCL2 c.107G>T alteration was observed in <0.001% (2/277,084). A similar amino acid change has been observed in an affected individual: _x000D_ _x000D_ A similar missense change affecting the same amino acid c.107G>A (p.C36Y) was reported in a patient with spastic paraplegia mild mental retardation, and no amyotrophy (Ishiura, 2014). The altered amino acid is conserved throughout evolution:_x000D_ _x000D_ The p.C36 amino acid is highly conserved in available vertebrate species. In silico prediction is conflicting:_x000D_ _x000D_ The p.C36F alteration is predicted to be possibly damaging by Polyphen and tolerated by SIFT in silico analyses. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Charcot-Marie-Tooth disease type 2 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 07, 2023 | This sequence change replaces cysteine, which is neutral and slightly polar, with phenylalanine, which is neutral and non-polar, at codon 36 of the BSCL2 protein (p.Cys36Phe). This variant is present in population databases (rs147314661, gnomAD no frequency). This variant has not been reported in the literature in individuals affected with BSCL2-related conditions. ClinVar contains an entry for this variant (Variation ID: 246509). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt BSCL2 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
BSCL2-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Dec 06, 2023 | The BSCL2 c.299G>T variant is predicted to result in the amino acid substitution p.Cys100Phe. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0085% of alleles in individuals of Latino descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Congenital generalized lipodystrophy type 2;C2931276:Hereditary spastic paraplegia 17;C4014700:Severe neurodegenerative syndrome with lipodystrophy;C5436838:Neuronopathy, distal hereditary motor, type 5C Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Apr 12, 2022 | - - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jul 03, 2024 | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 18790819) - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at